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Despite the relatively recent realisation of biosimilar: the first PubMed indexed article was 
published in August 2004, the first biosimilar somatropin was approved by the European 
Medicines Agency in April 2006 and that the MeSH term “biosimilar pharmaceuticals” was 
only introduced in 2012; much have already been written about raising the awareness of 
differences between biosimilars and originating pharmaceuticals.  In brief, biosimilars are 
large 3-dimension complex molecules. All steps of the production and purification process 
can significantly influence both the biological and clinical properties of the biosimilar hence 
there is greater process-related validity that can impact on efficacy and safety of the end-
product pharmaceutical. 
 
The biosimilar market is potentially the single fastest growing pharmaceutical sector.  The 
current biosimilar market represents 16% of the global pharmaceutical expenditure.  
However, the biosimilar pharmaceutical market is growing at a compound annual growth rate 
of 65.8% as compared to some 15% for small molecule generic pharmaceutical.  By 2020, 12 
biological products which have a global sale of US$67bn will come off patent by 2020.  This 
has stimulated the emergence of non-conventional pharmaceutical investors such as Fujifilm 
and Samsung as well as host countries such as Brazil, Mexico, China, India, South Korea, 
Turkey and Russia, which view biosimilars as a key macroeconomic driver of growth.  
Furthermore there is high expectation from health care authorities and insurer that cost saving 
will also result from the use of biosimilar such as the use of small molecule generic.  
Consequently there is much interest on biosimilars from insurers on seeing biosimilar as a 
mean of containing raising healthcare costs and also interest from pharmaceutical 
manufacturers because of demands, the lower costs of entry as compare to coming out with 
new pharmaceuticals. 
 
The consideration of biosimilar regulation, however, demands attention beyond quality, 
safety and efficacy.  The potential implications of extended patent protection, international 
trade and globalisation require a congruent policy approach to their regulation. 
 
In Australia, prior to entry into Australian market, the regulation of biosimilar need to 
consider intellectual property implications, specifically use of copyright, trade mark, patent 
registration as well as Australia’s obligations under international treaties such as Australia-
US Free Trade Agreement.  Patent has often been viewed as a mean of incentivising 
innovation. To that extent economic imperatives have been used as a justification for wider 
intellectual property.  Pharmaceutical manufacturers often applied for separate patent 
protection on end-product and the process of manufacturing.  However, unlike small 
molecule generic, downstream in biosimilar is much more closely linked to the upstream 
product.  Therefore restriction on upstream patent prevent downstream innovation.  The 2013 
Raising the Bar amendment to the Patent Act aimed to increase the threshold for obtaining 
patent.  The new test under the amendment required the “ordinary skilled person” to now 
consider information outside of one’s jurisdiction.  With globalisation and the higher 
threshold, this may mean researchers and pharmaceuticals manufacturers are less likely to 
publish their findings prior to entry into market hence locking up knowledge.  Furthermore, 
there is also the issue with the use of traditional medicines of which biological 
pharmaceutical is derived. 
 
At entry into market, there is the issue of use of confidential information when Therapeutic 
Goods Administration adjudicates on quality and safety.  Internationally, the European 
Medicines Agency has led the regulation of the quality, safety and efficacy of biosimilars; 
however, many countries have developed their own biosimilar regulatory frameworks.  
Despite the similarity of these with European guidelines, differences do exist across 
jurisdictions and have implications for cross-jurisdictional registration and regulation.  For 
instance, comparison of biosimilar product stability profiles not required in Japanese 
biosimilar regulation; Canadian, European Union, South Africa expressly demand for 
sufficient duration to allow detection of relevant differences in immunogenicity between 
biosimilars and reference product as compared to other jurisdictions. 
 
Post-entry into market, there is the issue of access especially via Pharmaceutical Benefits 
Scheme, the need for greater prescriber and dispenser awareness especially in the context of 
what is interchangeable or substitutable. Under the National Health Act, biosimilar under 
section 99ACEA is defined narrower as “same pharmaceutical item” or “same drug” whilst 
the regulation 2.14 (Schedule 1 items 3.1 – 3.2) defined biosimilar more broadly as “same 
active ingredient and the same form and manner of administration as an existing special 
pharmaceutical product”.  There is disparity in the definition under the Act and this has direct 
implication on what is interchangeable and/or substitutable.  Furthermore, the definition also 
have implications for F1-F2 pricing of pharmaceuticals which was introduced to contain costs 
in the Pharmaceutical Benefit Scheme.  All the current biosimilar products in Australia are 
still in F1 pricing. 
 
Notwithstanding the fact that Australia is a relatively small pharmaceutical market and that 
there are only 14 biosimilar products currently approved for use, Australia’s geographical 
proximity to pharm-emerging countries and its trade relation with the major pharmaceutical 
markets have positioned Australia in a unique position to influence international development 
and regulation of biosimilars.  
 
Focusing on China, there are two significant developments in People Republic of China 
(China) in recent time which worth mentioning.  In April 2009, the State Council passed the 
Deepening the Health Care System Reform which mandates increased Basic Medical 
Insurance coverage from 65% of population to 90% by 2011 and to revise the Essential Drug 
Lists.  These aim to establish an universal healthcare systems by which all Chinese citizens 
will be able to access affordable pharmaceutical and medical care.  We are also now coming 
towards the end of China’s 12th Five-Year Plan (2011-2015) which biosimilar was identified 
as a one of the seven macroeconomic drivers for growth and Chinese Government has 
invested significantly in promoting biosimilar market. Twenty biotech zones were set up 
nationally. This in return attracted significant interest from the top 20 multinational 
pharmaceutical companies.  The China’s biologic market is worth US$1.5bn and 40% comes 
from biosimilar. The compound annual growth rate of biosimilar in China is 25-30% over the 
past decade. If market continues to grow at 25%, biosimilar market in China could grow to 
US$2bn, around 20% of the global biosimilar market, by 2015. China has a potential market 
size of 600-800 bn RMB according to Chinese Academy of Science hence the biosimilar 
market was identified as a key sector in the 12th Five-Year Plan. There are now over 100 
biologicals in China with 47 1st generation biosimilars. This is to be compared with 20 
biosimilars currently approved by the European Medicines Agency.  Furthermore, the China 
State Food & Drug Administration since April 2011 mandated Good Manufacturing Practice 
for pharmaceutical manufacturing so as to ensure quality and safety but also to be able to 
compete internationally through export.  The average price cut of biosimilar is 60% as 
compared to 23% in Europe and 20% in USA. 
 
The challenges that Australia and China are confronted with may seem quite different but at 
the heart of it, both countries want economic growth while ensuring quality and safety, and 
equitable access.  The Australia’s National Medicines Policy (2000) potentially provides the 
foundation for a partnership approach to biosimilar regulation, minimise duplication of 
regulatory efforts while at the same time fostering a viable pharmaceutical industry.  Issue 





David is an early career academic with the School of Clinical Sciences at the Queensland 
University of Technology. His research focuses on quality use of medicines and expanded 
scope of health professional practice.  David holds a Bachelor of Law from Notre Dame 
University (2011), Doctor of Public Health from Curtin University (2010), and a Master of 
Medical Science in Surgery from University of Western Australia (2003).  David received 
some $400,000 in competitive research grant as chief investigator and a $3m grant as an 
associate for building a rural GP Superclinic. To date, David had published 64 monographs, 
and currently serves on the committee of the Public Health Association of Australia - Primary 
Health Care Special Interest Group and as a Director on the Board of the Young Australia 
League Inc. 
